Monitoring of RAS mutant clones in plasma of patients with RAS mutant metastatic colorectal cancer

Fernández Montes, A; Élez, E; Vivancos, A; Martínez, N; González, P; Covela, M; de la Cámara, J; Cousillas, A; Méndez, J. C.; Graña, B.
Clin. transl. oncol. (Print) ; 24(6): 1209-1214, junio 2022. tab
Artículo en Inglés | IBECS (España) | ID: ibc-203820

Documentos relacionados

  1. Multiplexed 3D atlas of state transitions and immune interaction in colorectal cancer.
  2. [A Case of Pembrolizumab Therapy Markedly Effective for Advanced Recurrent Colorectal Cancer].
  3. Colorectal cancer clocks in on TIME.
  4. Phase II study of durvalumab monotherapy in patients with previously treated microsatellite instability-high/mismatch repair-deficient or POLE-mutated metastatic or unresectable colorectal cancer.
  5. Anti-PD-1 therapy for advanced colorectal cancer based on intestinal microecology.
  6. Monitoring of RAS mutant clones in plasma of patients with RAS mutant metastatic colorectal cancer.
  7. From organoids to bedside: Advances in modeling, decoding and targeting of colorectal cancer.
  8. The emergence of RAS mutations in patients with RAS wild-type mCRC receiving cetuximab as first-line treatment: a noninterventional, uncontrolled multicenter study.
  9. Organoid screening reveals epigenetic vulnerabilities in human colorectal cancer.
  10. Immunological and prognostic significance of tumour necrosis in colorectal cancer.